Borregaard (BRG) Pre-close call summary
Event summary combining transcript, slides, and related documents.
Pre-close call summary
16 Jun, 2026Executive summary
Outlook for 2026 reiterates expected sales volumes for BioSolutions and BioMaterials, with some product mix and pricing headwinds in the near term.
Geopolitical tensions, especially the Middle East conflict, are causing uncertainty, impacting demand and costs, but are seen as temporary with no structural demand change.
Cost inflation, particularly in energy and raw materials, is being addressed through targeted cost reduction measures and potential price adjustments.
Trading performance and revenue trends
BioSolutions full-year sales volume expected at 340,000 tons; Q2 volume around 90,000 tons, with a less favorable product mix than last year.
BioMaterials full-year sales volume guided at 155,000–160,000 tons, up from 146,000 tons in 2025; Q2 volume expected at 40,000–42,000 tons.
Fine Chemicals sales prices for bioethanol expected to remain stable; intermediates volume to increase versus 2025.
Profitability and margins
Average sales price for BioMaterials expected to be 3–4% lower in H1 2026 versus H2 2025, mainly due to product mix.
Net cost impact from raw materials, energy, and logistics estimated at NOK 40–60 million negative year-over-year for Q2, despite a 15% reduction in wood costs.
Energy costs are significantly higher, with Norwegian electricity prices up 75% and natural gas up over 90% year-over-year.
Latest events from Borregaard
- Scaling high-value bio-based specialities through disciplined growth and investment.BRG
Corporate presentation - Record Q3 EBITDA of NOK 557m; Q4 faces cost, mix and maintenance headwinds.BRG
Q3 2026 - Sharpened focus on specialization and high-value growth targets 5% annual revenue and 25% EBITDA margin.BRG
CMD 2026 - Specialisation, sustainability, and innovation fuel growth in high-value bio-based markets.BRG
Corporate presentation - Q2 revenues and cash flow rose, but Alginor impairment and higher costs hit profit.BRG
Q2 2026 - Specialisation, innovation, and sustainability drive growth and strong financial performance.BRG
Company presentation - Specialisation, sustainability, and innovation drive growth and value in advanced biorefinery markets.BRG
Corporate presentation - EBITDA fell 16% year-over-year as cost inflation and weaker BioSolutions weighed on results.BRG
Q1 2026 - Specialization, innovation, and sustainability drive growth, backed by strong financials and investment.BRG
CMD 2024